Skip to content. | Skip to navigation

Garvan Institute

Sections
 

Laybutt

 

Diabetes occurs as a result of pancreatic beta cell failure. In both Type 1 and Type 2 diabetes, beta cell failure is characterised by insulin secretory defects, loss of insulin content and beta cell destruction. In Type 1 diabetes, this is mediated by cytokines that are produced as a part of an autoimmune and inflammatory process. In Type 2 diabetes, elevated lipid and glucose levels occurring as a result of high fat diets, obesity and insulin resistance are thought to contribute. The beta cell is a highly specialised cell with a unique metabolic profile and differentiation specifically geared towards making these cells able to sense fluctuations in circulating glucose levels and secrete insulin accordingly.

 

Our studies have shown that beta cell secretory defects in diabetes and in islet transplants are associated with a loss of the specialised expression pattern of genes that optimises insulin secretion. However, the molecular and cellular mechanisms responsible for this loss of beta cell differentiation are not known. It has recently emerged that cytokines, lipids and high glucose induce stress within the endoplasmic reticulum (ER) compartment of the cell. Pancreatic beta cells possess a highly developed ER, which is required for the processing, folding and export of vast quantities of newly synthesised insulin. We are investigating ER stress as an exciting potential mechanism for beta cell dysfunction and destruction in both types of diabetes.

 

Staff

 


Jeng Yie ChanPhD Student
Jeng Yie (Jenny) Chan
Honorary Researcher
Mia Akerfeldt

 

 

See also:

Biden Research Group

Schmitz-Peiffer Research Group

 

News

 

Hope for people with Type 2 diabetes – insulin master switch uncovered

MEDIA RELEASE: 22 Sep 2011
Garvan scientists have discovered that a single gene controls a very complex process, apparently forming the crucial link between eating a high fat diet and developing diabetes. Compounds are already being developed for blocking the gene – known as Id1 – as it has known adverse effects in cancer. This drug development work would very much shorten the path from discovery to prospective treatment in the case of diabetes.
 
 

Potential to prevent loss of insulin in Type 2 diabetes

MEDIA RELEASE: 14 Jul 2008
Until now, it was thought that the processes leading to the death of insulin-secreting pancreatic cells were similar in both types of diabetes. Scientists at Garvan have now shown that the process is quite different in the two diseases. They have also identified a promising therapeutic target for people with Type 2 diabetes
 
 

Personal tools